Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study
Omer Elneima, Hamish McAuley, Olivia C. Leavy, James D. Chalmers, Alex Horsley, Ling‐Pei Ho, Michael Marks, Krisnah Poinasamy, Betty Raman, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Victoria Harris, Linzy Houchen‐Wolloff, Ruth Saunders, Neil Greening, Matthew Richardson, Jennifer K Quint, Andrew Briggs, Annemarie B Docherty, Steven Kerr, Ewen M Harrison, Nazir Lone, Mathew Thorpe, Liam G. Heaney, Keir Lewis, Raminder Aul, Paul Beirne, Charlotte E. Bolton, Jeremy Brown, Gourab Choudhury, Nawar Diar Bakerly, Nicholas Easom, Carlos Echevarria, Jonathan Fuld, Nicholas Hart, John R. Hurst, Mark G. Jones, Dhruv Parekh, Paul Pfeffer, Najib M. Rahman, Sarah Rowland‐Jones, A. A. Roger Thompson, Caroline J. Jolley, Ajay M. Shah, Dan Wootton, Trudie Chalder, Melanie J. Davies, Anthony De Soyza, John Geddes, William Greenhalf, Simon Heller, Luke Howard, Joseph Jacob, Gísli Jenkins, Janet M. Lord, William D‐C Man, Gerry P McCann, Stefan Neubauer, Peter Openshaw, Joanna C. Porter, Matthew Rowland, J. T. Scott, Malcolm G. Semple, Sally Singh, David Thomas, Mark Toshner, Nikki Smith, Aziz Sheikh, Christopher E. Brightling, Louise V. Wain, Rachael A Evans, PHOSP-COVID Collaborative Group, Christopher E. Brightling, Rachael A Evans, Louise V. Wain, James D. Chalmers, V C Harris, L P Ho, Alex Horsley, Michael Marks, K Poinasamy, Betty Raman, A Shikotra, Amisha Singapuri, Christopher E. Brightling, R A Evans, L V Wain, Rowan Dowling, C Edwardson, O Elneima, Simon J. Finney, Neil Greening, B Hargadon, Victoria Harris, L Houchen-Wolloff, Olivia C. Leavy, H J C McAuley, Christopher E. Overton, Tatiana Plekhanova
Abstract
Key Features: The Post-Hospitalisation COVID-19 (PHOSP-COVID) study is a national UK multicentre cohort study of patients who were hospitalized for COVID-19 and subsequently discharged. PHOSP-COVID was established to investigate the medium- and long-term sequelae of severe COVID-19 requiring hospitalization, understand the underlying mechanisms of these sequelae, evaluate the medium- and long-term effects of COVID-19 treatments and to serve as a platform to enable future studies, including clinical trials. Data collected covered a wide range of physical measures, biological samples and patient-reported outcome measures (PROMs). Participants could join the cohort either in Tier 1 only with remote data collection using hospital records, a PROMs app and postal saliva sample for DNA; or in Tier 2 in which they were invited to attend two specific research visits for further data collection and biological research sampling. These research visits occurred at 5 (range 2–7) months and 12 (range 10–14) months post-discharge. Participants could also participate in specific nested studies (Tier 3) at selected sites. All participants were asked to consent to further follow-up for 25 years via linkage to their electronic healthcare records and to be re-contacted for further research. In total, 7935 participants were recruited from 83 UK sites: 5238 to Tier 1 and 2697 to Tier 2, between August 2020 and March 2022. Cohort data are held in a Trusted Research Environment and samples stored in a central biobank. Data and samples can be accessed upon request and subject to approvals from https://www.phosp.org/data-sample-request/.